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Overall Outline
1. HIV & ART overview
◦ History, Epidemiology, transmission/risk, 
staging
◦ Med Class Overview, ART initiation
2. Treatment monitoring & Failure
◦ 2nd & 3rd line ART, toxicity/complications, 
monitoring
◦ Prevention
3. Opportunistic Infections & Hepatitis B
◦ OIs, ART considerations, Prophylaxis
◦ HBV dx, tx, surveillance, & HIV-HBV co-infection
4. Special Populations:
◦ Pregnancy, antenatal & intrapartum, infant care 
& pediatric
5. HIV/HBV Case-Based Application
1. Case Application
2. Wrap-up/review, miscellaneous items
5 session, 2 hours each
Source Materials
Liberia Integrated Guidelines for Prevention, Testing, Care, and Treatment of HIV and AIDS
◦ 5th edition, August 2019
WHO HIV Diagnosis, Treatment, and Opportunistic Infection Guidelines
◦ 2016, 2018 ART update
◦ https://www.who.int/publications/guidelines/hiv_aids/en/
WHO Hepatitis B treatment guidelines (2015)
◦ https://www.who.int/hepatitis/publications/hepatitis-b-guidelines/en/
Reference Materials
Department of Health & Human Services. HIV Guidelines. USA. https://aidsinfo.nih.gov/guidelines
Fundamentals of HIV Medicine. American Academy of HIV Medicine. Oxford University Press. 2017 
Edition. 
National HIV Curriculum. University of Washington & CDC. USA. https://www.hiv.uw.edu/
Outline
Mechanism of Resistance & defining terms
Resistance Pathways for each ART class




34yo on EFV/TDF/3TC. She has lost 20 pounds in 6 months with diarrhea.
She discloses that she generally takes her meds 3-4 days a week. She misses medications on 
days when she travels to a nearby village to sell goods and leaves early in the morning.
Next step?




ART = Selective Pressure
Determines Viral Fitness
Viral Population
The most fit virus prevails at any given time point






















































Successful ART VL not detected
Potential 
Treatment Failure
Routine VL detectable (even if < 1,000)
Confirmed 
Treatment Failure
Targeted or repeat VL > 1,000
AND
Patient on NNRTI-based regimen*
AND
Good adherence for 3 months prior
*genotype for INSTI- or PI-based
Genetic Barrier to Resistance






















Kuritzkes et al 2003; Bositis 2019
number mutations required   
to confer resistance
time until resistance
Genetic Barrier to resistance
More “forgiving” regimen
Genetic Barrier
Number of mutations needed to 
confer resistance
Cross-resistance
Resistance to 1 agent in a class à resistance to other agents in the same class
First generation NNRTI & INSTI
◦ High level of cross-resistance
NRTI
◦ Varies
◦ emtricitabine (FTC) & lamivudine (3TC) = complete cross-resistance
PI & second-generation NNRTI
◦ Cumulative progressive resistance mutations expands cross-resistance
Adherence
“What challenges have you had taking your ARV?”
“What days / times are you most likely to forget your ARV?”
“Everyone has difficulty taking meds every day. When was 
the last time you were not able to take your ARV, and how 
many times in the past week, month were you unable?”
Root cause: there is always a reason (or reasons)
◦ Stigma & disclosure
◦ Socio-economic barrier






• Join with daily routines (meal, cleaning)
• Cell phone alarm
• Take meds with another person
• Keep a med diary
Goal: to help the patient
• No policing
• Encourage transparency
Intensive Adherence Counseling (IAC)
for any sign of poor adherence
for any detectable Viral Load (even is <1k)
Patient & Treatment Supporter
Education on ART, adherence, monitoring, failure, & 
resistance
Indentify Specifics
• Travel, Work, Education
• Stigma, Privacy, Domestic Difficulties
• Substance Use
• Mental Health / Depression
Action Plan
• Specific
• Written on Patient Card
• Monthly appointments
• Pill Counts
• Action Plan review
• Viral Load in 3mo
Stopping ART considered if:
• Chronic poor adherence
• IAC counseling completed










[decreased incorporation of NRTI 
into DNA strand]
Excision







Resistance to: 3TC, FTC








K65R Resistance to: TDF, 3TC, ABC
+ *Common in monotherapy
Co-occurrence 

















Slide Adapted from Bositis 2019
Empiric NRTI Resistance
Monotherapy to TDF or 3TC (or PrEP with TDF/3TC)
◦ Likely M184V, possible K65R 
◦ Assume resistance to TDF, 3TC, & ABC
◦ Unlikely TAM = use AZT
Confirmed virological failure
◦ Assume resistance to NRTIs in regimen & switch:
◦ If on TDF or ABC –> AZT
◦ If on AZT –> TDF/3TC
May always continue 3TC after failure
◦ Inducing M184V decreases viral fitness
Assume Susceptibility to: AZT
*may give 3TC (AZT/3TC combo) or TDF
(to select for M184V/K65R to ^ AZT susceptibility)
3TC and/or TDF
failure
Assume M184V / K65R
Resistance: 3TC, TDF, likely ABC
May give: TDF/3TC to induce 
M184V –> ^ TDF susceptibility
AZT
failure







Low Barrier to resistance
◦ Pre-existing mutations found in all ART-naïve patients are selected quickly – within 1 - 4 weeks!
◦ All NNRTIs bind in a similar location
HIV-2 – intrinsically resistant to all NNRTI






Resistance to EFV +NVP Highly fit virus
NVP
Y181C Resistance to NVP
Resistance to EFV 
quickly develops








Barrier to resistance is HIGH
1. darunavir / ritonavir
2. lopinavir / ritonavir
3. atazanavir / ritonavir
Multiple mutations generally needed for resistance
◦ Major – cause resistance
◦ Many have cross-resistance
◦ Often decrease viral fitness
◦ Minor – do not affect susceptibility but may enhance viral replicative 
capacity
Multiple Mutations
Generally required to 
alter enzymatic activity
PI Resistance Principles
Viral Resistance Mutations are Rare – Adherence / absorption predominates
Virologic Failure more likely if prior treatment experience with a different PI
Important to confirmed good adherence prior to viral load!
Suspected Treatment 




LPV/r    – lopinavir / ritonavir
ATV/r    – atazanavir / ritonavir




^ Susceptibility to other PIs
DRV + r
I50V Major Resistance to DRV/r
Minor Resistance to LPV




Significant cross-resistance to ATV
Empiric PI Resistance
Assume I50L
*may trial LPV/r or DRV/r AND/OR INSTI
ATV/r
failure Ensure good adherence
Assume I50V (LPV/r & DRV/r resistance)
Will need INSTI, ?ATV/r if no prior tx history
DRV + r
failure Ensure good adherence
Assume ATV/r resistance
May trial DRV + r AND/OR INSTI
LPV/r





DTG Highest barrier to resistance
High Barrier to Resistance: Viral Resistance Mutations are Rare – Adherence / absorption predominates
Time on regimen likelihood of resistance=
◦ Little cross-resistance to earlier INSTIs (elvitegravir [EVG] & raltegravir [RAL])
◦ Very little phenotypic resistance seen even in patients on failing regimens
INSTI Resistance Pathways & 
Empiric Resistance
If documented virologic failure:
ADD Boosted PI (DRV + r)
Change “Base”
DTG
failure Ensure good adherence
Genotype
Back to our case…







When to do VL
* Any of the following: Significant unintended weight loss, failure to thrive, new or worsening HIV-related disease (suspected or confirmed)
Wait
Well Not Well *
ART clinic visit
Less than 6 
Months
Around milestone
















































Successful ART VL not detected
Potential 
Treatment Failure
Routine VL detectable (even if < 1,000)
Confirmed 
Treatment Failure
Targeted or repeat VL > 1,000
AND
Patient on NNRTI-based regimen*
AND
Good adherence for 3 months prior









































We have determined that our patient has a failed EFV/TDF/FTC regimen.
◦ What is your next step?
2nd line ART
*1st line START 



















Fast forward 3 years.





Assumes likely resistance to at 
least 2 prior agents
◦ Assumes failure to prior treatment 
with core of:
◦ For likely NRTI resistance, “flip” the 




2 Core Agents Backbone
DTG*+
*DTG is BID if INSTI resistance






If failed on: Switch to:
Case (cont)
Our patient now on DRV/r/DTG/AZT/3TC presents with asymptomatic viral load of 1,230
◦ What do you think is going on here?
◦ What do you do?
Genotype Overview
Obtain for failure evaluation while on PI- or INSTI-based regimens 
◦ Rationale: to differentiate resistance virus from poor adherence / low drug levels
When to obtain a genotype: while the patient is taking failing ART with detectable virus!
◦ Genotyping is sensitive to resistance mutations only if they are present in a minimum of ~20% of 
circulating virus at the time of the test
◦ In the selective presence of ART à mutant virus is advantaged and present
◦ In the absence of ART à wild-type virus is generally most fit and predominates
A patient with history concerning for prior virologic failure due to resistance is currently off ART.
◦ What are your next steps?
Obtaining & interpreting a Genotype
Stanford Resistance DatabasePCR -> averaged genetic sequence -> compared to wild-type 
Switching regimen (Table 10)






Failure to improve after 
2 mo of continued ART & 
symptom management
Switch to Alternative 2
Contraindication or 
adverse effect









































◦ Q 4 weekly visits
If stable, transition to Q 8 weekly visits
** Remember the “tail” if switching off these! **
EFV NVPor
EFV & NVP are present in decreasing concentration for 7 days after stopping
When stopping, give at least 7 days of fully active ART regimen to prevent EFV 
or NVP resistance from developing during the “tail”
ART Adverse Effects, medication 
interactions
These are numerous, and difficult to remember
◦ The Liberian treatment guideline has an excellent symptom-based guide to adverse effects and 
complications
For medication interactions – focus on a few high-yield culprits and forget the rest, just use:
https://hiv-druginteractions.org/
Nucleoside Reverse Transcriptase Inhibitor
(NRTI) – Adverse Effects & Caution
tenofovir [TDF] lamivudine [3TC]
abacavir [ABC]
zidovudine [AZT]
• Fully active against HBV 
• Dose adjust if CrCl <50 (q48hr for Crl 30-49, q72 for 10-29)
• Renal Toxicity / Fanconi Syndrome
• Glucosuria, proteinuria, aciduria,  CKD, hyperphos, 
hypoK
• Osteoporosis
• Tenofovir alafenamide (TAF)
• Well tolerated
• In all 1st & 2nd line regimens
• HBV-active but not preferred for mono-therapy
• Decrease dose for CrCl <50
• Hypersensitivity reaction = absolute contraindication
• Increases cardiovascular disease risk
• No renal dose adjustment in CKD
• Q 12 hour dosing
• Bone marrow suppression = anemia & leukopenia
• myopathy
• lipodystrophy
• Lactic acidosis (rare if not co-administered with stavudine)
• Dose adjust for CrCl <15 – take 300mg daily
Nucleoside Reverse Transcriptase Inhibitor
(NRTI) – Adverse Effects & Caution (cont)
stavudine [d4t]
• Not included in Liberia 5th edition guideline
• Peripheral neuropathy
• Lactic acidosis (esp in combination with AZT)
• lipodystrophy
• dyslipidemia
Non-Nucleoside Reverse Transcriptase Inhibitor
(NNRTI) – Adverse Effects & Caution
nevirapine [NVP] efavirenz [EFV]
• Hypersensitivity reaction
• Rash and/or hepatotoxicity, may be with fever, 
renal injury, mucous membrane involvememtn
• Most common in women, those with HBV co-
infection & high CD4
• Caution if CD4 is:
• >250 in women
• >400 in men
• Neuropsychiatric effects
• Nightmares, depression, psychosis, ^ suicidality, 
headache
• Take at bedtime on empty stomach to minimize adverse 
effects
• ~15% erythematous maculopapular exanthema
• Hepatotoxicity – do not use if cirrhosis CTP Class B or C
• Unfavorable lipid profile effects
• gynecomastia
• QTc prolongation
No renal dose adjustment!
Protease Inhibitor (PI) –
Adverse Effects & Caution
lopinavir / ritonavir [LPV/r] atazanavir / ritonavir [ATV/r]
darunavir + ritonavir [DRV+r]
• Diarrhea
• Hyperlipidemia
• Liquid formulation is 40% alcohol by volume
• Benign hyperbilirubinemia
• nephrolithiasis
• Abdominal pain, diarrhea
• Rash (within 4wks of start, self-resolves)
ritonavir [r]
• Inhibits liver enzyme CYP3A
• MANY drug-drug-interactions
• Diarrhea, nausea, abdominal pain
No renal dose adjustment!
Integrase Strand Transfer Inhibitor (INSTI)
- Adverse Effects & Caution 
dolutegravir [DTG]
• Mild side effects: headache, insomnia, nausea – generally self-resolve
• If known liver disease (ie, HBV) -> check LFTs before & after initiation
• BID with rifapentine for MTB treatment
• Neural tube defects if taken at conception
• Tsepamo Study: NTD in 3/1,000 on DTG vs 1/1,000 on other ART
• WHO now recommends DTG for use in women of childbearing age. Countries give 
varying recommendations.
• Increase in serum Creatinine (by ~0.15 on average) without CKD
Zash et al 2019
No renal dose adjustment!
NNRTI & INSTI Key Drug-Drug Interactions
nevirapine [NVP] efavirenz [EFV]
dolutegravir [DTG]
• DO NOT give with: rifampicin or rifapentine • DO NOT give with: simvastatin
• AVOID with: clopidogrel
• May decrease level of: atorvastatin
• metformin should not exceed 1 gram total daily dose
• Separate from divalent cations (ie, iron, calcium, 
magnesium) – take DTG 2hrs before OR 6hrs after
Worst offenders!!
Boosted PI Key Drug-Drug Interactions
lopinavir / ritonavir [LPV/r]
atazanavir / ritonavir [ATV/r]
darunavir + ritonavir [DRV+r]
• Antacids: take ATV 2hrs before OR 1hr after antacid
• H2 antagonist: take with ATV/r OR 10hrs before ATV/r
• PPI: do not co-administer
• PPI: max 40mg omeprazole
class-wide OR ritonavir
• Statins: 20mg atorvastatin max; NO simvastatin
• Variable effects on warfarin
• Most anti-convulsants lower PI, NNRTI, INSTI levels
• Do NOT give with: rifampicin, rifapentine
• Increases concentration of: Beta-blockers (except 
atenolol, labetalol) & calcium channel blockers
• No significant unique interactions
NRTI & NNRTI Switches by adverse effects
AZTABC
Hypersensitivity Reaction:


















Any suspected hypersensitivity reaction = 
STOP the ART & DO NOT re-challenge 
Give dizziness, drowsiness & 
nightmares 4 weeks to resolve
PI & INSTI Switches by adverse effects
LPV/rATV/r








Start by clinical scenario
Condition Timing of ART start ART
Anemia (<8g/dl) NOW DTG / TDF / 3TC
Pedi: DTG + ABC / 3TC
Active MTB Within 14 days DTG / TDF / 3TC
Pedi <30kg: EFV
Jaundice Initial evaluation first EFV / TDF / 3TC
DTG only if severe liver dz & HBV/HCV ruled out
Renal Failure Within 7 days NVP + ABC/3TC
Psychiatric Illness History NOW DTG / 3TC / TDF
NVP + TDF / 3TC
Pregnancy NOW DTG / TDF / 3TC
New HIV+ in labor NOW DTG / TDF / 3TC
Cases
55yoM with CKD recently started on DTG/ABC/3TC develops a cough and vomiting 2 weeks after 
starting.
◦ What is going on? Do you switch ART, and if so to what?
23yoF planning pregnancy soon sees you in clinic for new HIV diagnosis & ART start.
◦ How do you counsel her on ART options?
34yoF presents with suicidal ideation after starting ART recently. She does not know her meds 
and medical records are missing.
◦ What ART might she be on, and what do you suggest?
Cases
59yoM with HTN on NVP/TDF/3TC presents with 20lb weight loss and polyuria over 3 months.
◦ What do you suspect? What studies do you order? What is your recommendation?
63yoF on NVP/AZT/3TC notes an increasingly protuberant abdomen and thinning facial soft tissue.
◦ What do you suspect? What is your recommendation?
33yoM on NVP/TDF/3TC has VL 2,350 after IAC and 3 months of good adherence.
◦ What is your recommendation?
43yoF on LPV/r/TDF/3TC with chronic diarrhea without weight loss for 3 months.
◦ What do you suspect? What is your recommendation?
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